© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
Clinical Trials on Alzheimer's Disease Conference
Masupirdine Improves Agitation and Aggression in Alzheimer Disease
December 01, 2021
A phase 3 trial has been initiated to further study masupirdine’s effect on agitation in patients with Alzheimer dementia.
Lecanemab Reduces Amyloid in Patients With Early Alzheimer Disease
November 30, 2021
Data show a clinical benefit via a reduction in brain amyloid as early as 3 months in the open-label extension period.
Key Takeaways From a Study of FUS in Early AD Dementia: Ali Rezai, MD
November 28, 2021
The executive chair at the Rockefeller Neuroscience Institute at West Virginia University shed light on early data from a small sample of patients with early Alzheimer disease who underwent focused ultrasound treatment. [WATCH TIME: 5 minutes]
Next Steps, Future Development of FUS Technology in Alzheimer Disease: Ali Rezai, MD
November 22, 2021
The executive chair of the Rockefeller Neuroscience Institute at West Virginia University discussed the potential of focused ultrasound for patients with AD, as well as key takeaways for clinicians from a recent study. [WATCH TIME: 5 minutes]
Low-Dose Lithium Shows Mixed Benefits for Alzheimer, Fails to Improve Behavioral Complications
November 21, 2021
Despite not being significantly superior to placebo on agitation and aggression, lithium showed a greater reduction in those with high Young Mania Rating Scale scores.
Evaluating Early Data on Focused Ultrasound for Patients With Alzheimer Disease
November 19, 2021
Ali Rezai, MD, executive chair at the Rockefeller Neuroscience Institute at West Virginia University, outlined early data from a clinical trial utilizing focused ultrasound to open the blood-brain barrier in patients with mild AD.
Applications of MRI-Guided FUS in Alzheimer Disease: Ali Rezai, MD
November 19, 2021
The executive chair of the Rockefeller Neuroscience Institute at West Virginia University spoke on how technology can be used to open the blood-brain barrier in patients with AD. [WATCH TIME: 7 minutes]
Neflamapimod Displays Robust Efficacy in Pure Lewy Body Dementia Pathology
November 19, 2021
The magnitude of neflamapimod’s effect on several efficacy measures proved to be consistent with the mechanism of action and prior preclinical data, with p-tau181 data suggesting a stronger effect on nonmixed Lewy body pathology.
Investigating the Use of MRI-Guided Focused Ultrasound in Alzheimer Disease
November 17, 2021
Ali Rezai, MD, executive chair of the Rockefeller Neuroscience Institute at West Virginia University, provided an overview of FUS technology and its use in opening the blood-brain barrier.
AMX0035 Meets Primary Safety and Tolerability End Point in Alzheimer Disease
November 17, 2021
A higher incidence of gastrointestinal events was observed in the treatment group compared with placebo, similar to what was seen in clinical trials of AMX0035 in amyotrophic lateral sclerosis.